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Abstract 
Background: Night shift work has been associated with an increased risk for breast and prostate 
cancer. The effect of circadian disruption on sex steroid production is a possible underlying 
mechanism, underinvestigated in humans. We have assessed daily rhythms of sex hormones and 
melatonin in night and day shift workers of both sexes.  
 
Methods: We recruited 75 night and 42 day workers, aged 22-64 years, in different working 
settings. Participants collected urine samples from all voids over 24 hours on a working day. 
Urinary concentrations of 16 sex steroid hormones and metabolites (estrogens, progestagens and 
androgens) and 6-sulfatoxymelatonin were measured in all samples. Mean levels and peak time 
of total and individual metabolite production were compared between night and day workers.  
 
Results: Night workers had higher levels of total progestagens (geometric mean ratio (GMR) 
1.65; 95% confidence interval (CI) 1.17, 2.32) and androgens (GMR: 1.44; 95% CI 1.03, 2.00), 
compared to day workers, after adjusting for potential confounders. The increased sex hormone 
levels among night shift workers were not related to the observed suppression of 6-
sulfatoxymelatonin. Peak time of androgens was significantly later among night workers, 
compared to day workers (testosterone: 12:14 h; 10:06, 14:48 vs 08:35 h; 06:52, 10:46).  
 
Conclusions: We found increased levels of progestagens and androgens as well as delayed peak 
androgen production in night shift workers, compared to day workers.  
 
Impact: The increase and mistiming of sex hormone production may explain part of the 
increased risk for hormone-related cancers observed in night shift workers.  
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Introduction 
Night shift work has been associated with cancer risk in humans, especially after long-term 
exposure (1). The strongest epidemiological evidence, to date, is for female night shift workers 
and breast cancer (2-4) but there is also limited evidence on other hormone related cancers such 
as prostate (5, 6) and endometrial cancer (7). Several mechanisms have been proposed to explain 
the association between night shift work and cancer risk, including light-induced melatonin 
suppression, sleep disturbances and circadian disruption (8-10). An increase in sex hormones 
after night shift work has been a long discussed, though not confirmed, hypothesis, particularly 
relevant for hormone dependent tumors (11, 12). 
The circadian timing system is closely related to the endocrine system. A functional 
master clock located in the suprachiasmatic nuclei (SCN) of the hypothalamus is necessary for 
rhythmic steroid synthesis and excretion (13, 14). It has been hypothesized that exposure to light 
at wrong times, such as experienced during night shift work, can disrupt normal melatonin 
synthesis which in turn may increase estrogen production (11). Some observational studies 
reported higher plasma estrogen levels related to long-term exposure to night shift work in 
women (12, 15, 16). Although melatonin has potential anti-estrogenic effects (17, 18), an inverse 
association between endogenous melatonin and estrogens has not yet been confirmed in humans 
(15, 19-21). Lifetime exposure to higher levels of estrogens and androgens may increase breast 
cancer risk, while recent evidence also indicates that progesterone is an important hormone in 
breast cancer etiology (22-24). The possible effect of night shift work on estrogen, androgen and 
progestagen production is largely underinvestigated, especially in men, and might explain in part 
the increased risk of breast and prostate cancer observed among female and male night shift 
workers, respectively.  
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We assessed daily rhythms of urinary sex hormones and metabolites including estrogens, 
progestagens and androgens in permanent night and day workers of both sexes. We also 
examined the interrelations between urinary 6-sulfatoxymelatonin and sex hormones. We 
hypothesized that permanent night shift work would increase 24 hour sex hormone levels and 
alter the peak time of their production.   
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Materials and Methods  
Participants in this study were female and male night and day workers from 4 companies in 
Barcelona: two hospitals, a car industry and a train company. The selection procedures used for 
participant recruitment were the same in all participating companies. Study participation was 
offered to all workers in permanent day or night shifts through the Health and Safety departments 
of each company using leaflets and personal contacts. Enrolment was voluntary and there was no 
compensation for participating. All those initially agreeing to participation were enrolled and 
because of this selection procedure we cannot report participation rates. Our study sample was 
balanced across the four companies in terms of numbers of participants in each shift, however, 
the proportion of participants per company is not the same since these companies were very 
different in size and structure. 117 workers (42 day and 75 night workers) of both sexes (63 men 
and 54 women) aged 22-64 years, participated in the study. All but 2 women were hospital nurses 
and assistants. All but 4 men worked in the car industry and train company. Night shift nurses 
worked 10 hour shifts (21:00-07:00 h) on a short (2 days off-2 nights work-3 days off) and a long 
(2 nights work- 2 days off-3 nights work) working week alternately. Night shift car industry 
workers and train employees performed 8 hour shifts (22:00-06:00 h) on a schedule including 3 
and 5 consecutive nights per week, respectively. All day workers were engaged in fixed 8 hour 
morning shifts 5 days a week with starting times varying from 05:45 to 07:00 h depending on the 
working sector. Night workers were engaged in night shift work for at least 1 year and, although 
some day workers had a history of night shift work, this did not occur within a year prior to 
participation. Recruitment took place from March to June 2011. Subjects were not eligible if they 
had a history of cancer and for females if they had been pregnant in the previous 6 months or 
were currently taking oral contraceptives or hormonal therapy. Filter questions were included in 
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the study questionnaire to ensure that the exclusion criteria were fulfilled. The study was 
approved by the local ethics board and all participants signed an informed consent. 
We collected information on sociodemographics, lifestyle habits, night shift history, 
health symptoms and medication through a personal interview. Occupation information included 
start and stop times, number of shifts per week, main tasks and activities and years worked at 
night. Questions related to sleep duration, physical activity, smoking, alcohol and caffeine 
consumption were asked for both habitual use as well as for the 24 hours prior to study 
enrolment. For women information on reproduction history including parity and age of first full-
term birth was collected. Menopausal status was based upon cessation of periods and menstrual 
cycle phase on the days since last period (follicular phase: <11 days, mid-cycle phase: 11-16 
days, luteal phase: ≥17 days). Diurnal preference was assessed using the Morningness-
Eveningness Questionaire (25). Participants were asked to collect one urine sample from each 
natural void over a 24-h working day or night and store them at 4 ºC. Samples were transported 
on ice and frozen at -80 ºC until analysis.  
Concentrations of 16 steroid hormones and metabolites were measured in a total of 899 
urine samples, using gas chromatography and mass spectrometry (GC-MS). Analyses were 
performed by the Bioanalysis Research Group at IMIM, in Barcelona, Spain. Hormones and 
metabolites included estrogens (estradiol, estrone and estriol), progestagens (pregnanediol, 
pregnanetriol and 16-androstenol) and androgens (testosterone, epitestosterone, 
dehydroepiandrosterone (DHEA), androsterone, etiocholanolone, 11β-OH-androsterone, 
androstenedione, 6α-OH-androstenedione, 3α,5α-androstanediol, and 3α,5β-androstanediol). The 
procedure for preparing the samples was based upon routinely employed screening methods in 
doping control analysis (26). Briefly, 2.5 ml of urine were hydrolysed, extracted and derivatized, 
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and analyzed by GC-MS. The method employed was validated following internationally accepted 
criteria. The validation results proved linearity of the method from 1 ng/mL to 400 ng/mL for 
most steroids (r>0.99). For androsterone, etiocholanolone, pregnanediol, pregnanetriol and 16-
androstenol linearity was demonstrated up to 10000 ng/mL. Adequate interassay precision 
(coefficients of variation < 19%) were found for the quantification of all steroids at the assayed 
concentrations (Supplemental Table 1). The validity of the results for the samples was assessed 
by verifying the proper concentrations for all steroids in the quality control sample analyzed in 
the same analytical batch. Undetected values were replaced by the half of the limit of detection of 
each of the following metabolites: estradiol (N=45), estrone (N=10), estriol (N=21), 
epitestosterone (N=10), testosterone (N=5), 3α,5α-androstanediol (N=11), 3α,5β-androstanediol 
(N=9), androstenedione (N=23) and 6α-OH-androstenedione (N=31). For 16-androstenol (N=5) 
and androsterone (N=1), undetected values were due to the presence of interfering peaks at the 
retention times of the analytes that did not allow their proper quantification and were left as non-
detected. Urinary 6-sulfatoxymelatonin (aMT6s) concentrations, the major melatonin metabolite, 
were measured by the Chronobiology Group, University of Surrey, UK, (Stockgrand, Ltd., 
Guildford, Surrey, UK) using a radioimmunoassay (27) The intra-assay variability was 5.7% at 
3.3 ng/ml, 7.8% at 15.5 ng/ml and 6.1% at 28.3 ng/ml and the limit of detection was 0.2 ng/ml. 
Inter-assay variability was 8.7% at 2.6 ng/ml, 7.9% at 17.6 ng/ml and 10.3% at 31.3 ng/ml. 
Creatinine levels were determined in all urine samples by the same laboratory using the manual 
picric acid, sodium hydroxide colorimetric method (Randox Laboratories Ltd.). Limit of 
detection of the assay was 25.1 mg/dl and inter-assay variability was 7.6% at 87.4 mg/dl and 
9.9% at 198.3 mg/dl. All metabolite values were creatinine-standardized and quoted as ng/mg 
creatinine.  
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Statistical analysis 
Individual cosinor analysis was used to evaluate the rhythm of 6-sulfatoxymelatonin, individual 
sex hormone metabolites and total estrogen, progestagen and androgen production. Cosinor 
analysis is a curve fitting procedure used in the analysis of rhythms with a cyclic nature and an 
approximate 24-h period (28). The acrophase (peak time) and mesor (24-h mean) of the 
metabolites were derived for each subject. The validity of the cosinor-derived parameters was 
determined using the percentage variability accounted for the cosine curve (100% indicates that 
all data points fall on the cosine curve). The 24-h mean levels (median and interquartile range) 
and peak time (geometric mean and 95% confidence interval) were described for all metabolites 
in day and night workers and by sex and menopausal status. The correlation between aMT6s and 
sex steroid metabolites (24-h mean levels and peak time) was evaluated using Pearson 
correlations for the log-transformed variables. Generalized linear models were used to examine 
associations between shift work and log-transformed 24-h mean levels and peak time. Log-
transformation was applied to achieve a normal distribution of the variables. For 24-h mean 
levels regression estimates were back-transformed and presented as the geometric mean ratio 
(GMR) of levels in night vs day workers. Peak time difference was estimated as the geometric 
mean difference (GMD) of the predicted acrophases in night workers compared to day workers 
and expressed in hours. We used directed acyclic graph (DAG, Supplemental Figure 1) to select 
confounders a priori for each of the outcomes (mean levels, peak time). We included age, sex, 
education, diurnal preference, menopausal status, menstrual cycle phase, in basic models. We 
additionally adjusted models for variables (potential confounders and intermediate variables) that 
were significantly associated with at least one of the metabolites (list of variables shown in 
Supplemental Figure 1). To account for the possible effect of melatonin on steroid production, we 
adjusted in separate models for aMT6s levels or aMT6s peak time. In sensitivity analyses, 
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subjects with reported chronic health symptoms, any drug use and women with irregular 
menstrual cycles were excluded and results remained unchanged (data not shown). Statistical 
analysis was performed using the statistical package Stata version 12.1. 
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Results 
Night shift workers were older, heavier and reported more chronic symptoms and drug use, 
compared to day workers in both sexes but differences were not statistically significant (Table 1). 
Night shift workers had significantly lower Morningness-Eveningness scores (48.4 vs 55.2 in 
men and 46.7 vs 50.4 in women) indicating more evening preference, compared to day shift 
workers. Male night shift workers reported less current smoking (33.3 vs 42.9%), higher alcohol 
consumption (33.3 vs 14.3% consumed any alcohol) and shorter sleep duration (5.6 vs 6.4 hours) 
over the previous 24 hours, compared to male day workers. Male night workers were less likely 
to have university education compared to female night workers (17.9 vs 66.7%), however, no 
differences in the educational level was found between shifts for both sexes. Women had worked 
less nights over the previous 2 weeks compared to men (5.2 vs 6.8 nights) but had on average 
been engaged in night shift work for more years (15.4 yrs) compared to male night workers (10.8 
yrs). Men working at night reported earlier sleep onset on a working day (06:00-07:00 h) than 
women (07:00-08:00 h). Amongst females, night shift workers were more frequently 
postmenopausal (51.5 vs 20%), parous (90.9 vs 80%), and likely to report menstrual irregularities 
(30 vs 19.1%) and sleep problems (90.9 vs 85 %), compared to day workers. There were no 
differences in the distribution of womens’ menstrual cycle phases or menstrual cycle length 
between shift types.  
Table 2 shows the 24-h mean aMT6s and sex hormone levels in night and day workers 
among men, premenopausal and postmenopausal women. Levels of androgens and their 
metabolites (testosterone, DHEA, androsterone, 11β-OH-androsterone, 6α-OH-androstenedione) 
were higher among male night workers compared to day workers, although differences were not 
statistically significant. Amongst premenopausal women, testosterone (8.0 vs 4.0 ng/mg 
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creatinine/h) and 3α,5α-androstanediol (36.2 vs 21.3 ng/mg creatinine/h) levels were significantly 
higher in women working at night compared to day workers. Total progestagens were 
significantly higher among premenopausal night workers (3289 vs 1458 ng/mg creatinine/h), 
compared to day workers. Total estrogens were also higher in premenopausal night workers (26.3 
vs 21.3 ng/mg creatinine/h), though differences were not statistically significant. No differences 
were found between postmenopausal night and day shift female workers (Table 2). Comparisons 
in postmenopausal women were limited since the control day worker group only compromised of 
4 subjects and most of the samples with non-detectable estrogens belonged to this group.  
In the full study population (Table 3) night shift work was associated with significantly 
increased total progestagen levels (Geometric mean ratio (GMR) 1.65; 95% confidence interval 
(CI) 1.17, 2.32), after adjustment for a wide range of potential confounders. Individual 
progestagen metabolites were higher among night shift workers (pregnanediol: GMR 1.74; 95% 
CI 1.15, 2.64, pregnanetriol: 1.46; 1.06, 2.01, 16-androstenol: 1.32; 0.84, 2.01), compared to day 
workers. Total androgen production was also higher among night shift workers (GMR: 1.44; 95% 
CI 1.03, 2.00). All androgens and their metabolites were higher in night shift workers compared 
to day workers. Differences were statistically significant or of borderline significance for 
testosterone (GMR 1.43; 95% CI 0.95, 2.14), DHEA (1.38; 1.05, 1.82), androsterone (1.40; 0.97, 
2.02), 11β-OH-androsterone (1.42; 0.99, 2.04), 4-androstenedione (1.36; 1.05, 1.78), 6α-OH-
androstenedione (1.41; 1.09, 1.84), and 3α5α-androstanediol (1.38; 0.99, 1.91). Both estradiol 
(GMR 1.20; 95% CI 0.83, 1.74) and estrone (1.17; 0.86, 1.59) were higher in night shift workers 
but differences were not statistically significant. Levels of 6-sulfatoxymelatonin were lower in 
night compared to day workers (GMR 0.67 (0.51, 0.89). Differences in estrogen, progestagen and 
androgen levels between night and day workers persisted and if anything were more pronounced 
after additional adjustment for 6-sulfatoxymelatonin (Table 3). Figure 1 shows the estimates of 
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the individual metabolites in night workers compared to day workers in the two largest study 
groups: men and premenopausal women, adjusted for age, BMI and menstrual cycle phase 
(premenopausal women). Night shift work was associated with a 20-60% increase in individual 
androgens and their metabolites in both sexes. Testosterone was 2-fold (GMR 2.03; 1.06, 3.88) 
and pregnanediol almost 3-fold (GMR 2.75; 95% CI 1.28, 5.94) higher in premenopausal female 
night workers compared to day workers. Among premenopausal women, night shift workers 
showed higher progestagen and androgen levels across the three menstrual cycle phases but 
estimates became less precise as comparisons were based on smaller subject numbers 
(Supplemental Table 2).  
As shown in Table 4, peak time of testosterone (12:14 h vs 08:35 h), epitestosterone 
(13:35 h vs 09:11 h), DHEA (13:43 h vs 10:24 h) and etiocholanolone (12:40 h vs 09:46 h) 
occurred significantly later in night workers compared to day workers. After adjusting for 
potential confounders, all androgen metabolites showed a later peak time in night shift workers 
compared to day workers, statistically significant for epitestosterone (5.8 hours later; 95% CI 2.5, 
9.2), DHEA (3.4 hours; 0.6, 6.2), etiocholanolone (2.8 hours; 0.1, 5.6), 6α-OH-androstenedione 
(3.1; 0.1, 6.0) and borderline significant for testosterone (3.2 ; -0.6, 6.9) and 3α5β-androstanediol 
(3.1; -0.1, 6.3). Estriol peak time was also later in night workers (08:58 h; 07:38, 10:34) 
compared to day workers (06:12 h; 04:15, 09:02), although not statistically significant after 
adjustment for confounders. Peak time of aMT6s occurred 3 hours later in night workers (08:42 
h; 95% CI 07:48, 09:42) compared to day workers 05:36 h; 95% CI 05:06, 06:12). The effects of 
night shift work on the peak time of sex hormone production were attenuated after adjusting for 
aMT6s acrophase (Table 4). Effects of shift status on peak time were found in both sexes, but 
were stronger among men (Figure 2 and Supplemental Table 3).  
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We found no correlation between 24-h urinary production of aMT6s and estrogens, 
progestagens, and androgens (Supplemental Figure 2 and Supplemental Table 4). The percentage 
of cosinor fits was lower in sex hormones (40-45% for estrogens, 44-47% for progestagens and 
44-58% for androgens) compared to aMT6s (83%), considered the best marker of circadian 
phase. The peak time of aMT6s was positively correlated (p<0.05) with the peak time of 
testosterone (correlation coefficient r=0.41), epitestosterone (r=0.59), etiocholanolone (r=0.35) 
and 6α-OH-androstenedione (r=0.26) in men and with estrone (r=0.30) in women. Similar results 
were obtained in analyses stratified by shift status (Supplemental Table 5) and in multivariate 
analysis adjusting for confounders (results not shown).   
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Discussion 
We have evaluated the association of 16 sex hormones and their metabolites with night shift 
work using repeated samples over a 24-h period. Significantly increased levels of androgens and 
progestagens were observed among night workers compared to day workers in both sexes. 
Smaller differences, statistically non significant, were observed for estrogens. Night shift work 
was also associated with a later peak time for androgens in both sexes and estriol in women. The 
effect of night shift work on sex hormone levels was independent of melatonin production, while 
the observed delayed peak time of their production was mirrored by a phase delay in melatonin 
production, considered a reliable marker of circadian phase.  
The increase in estrogens, androgens and progestagens among night workers may be a 
biologically plausible mechanism for the link between night shift work and hormone dependent 
cancers. Higher levels of estrogens have been associated with breast cancer risk in women, as 
well as combined exposure to increased estrogens and progestagens (22, 24, 29, 30). Androgens 
also increase female breast cancer risk, either directly by increasing growth and proliferation of 
cancer cells, or indirectly via conversion to estrogen (31-33). In men, the role of androgens in 
prostate carcinogenesis has long been discussed but results are inconsistent (34). It has been 
hypothesized, at least for estrogens, that hormone metabolism may also play a role in cancer 
etiology (35). The present study has shown an increase of sex hormones and their metabolites as 
well as changes in their peak time of production in night shift workers. It is not yet known 
whether abnormally timed rhythms of sex hormone production may affect breast and prostate 
cancer risk in addition to higher levels. 
The increase in 24-h production of androgen and progestagen metabolites among night 
workers is a novel finding. A few studies, all in women, have evaluated sex hormones in spot-
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samples of urine in relation to night shift work (12, 15, 16, 20, 36). Similar to our results, two 
studies showed higher levels of progesterone and DHEA after recent night shift work and 
increased estrogens in women with long-term and any night shift work history (12, 15). However, 
2 nights of work in a rotating night shift schedule did not alter sex hormone levels (20, 36). 
Interestingly, higher testosterone was found among pregnant women with higher light at night 
exposure (37).There is some evidence for a possible direct effect of bright light on LH and FSH 
and subsequent stimulation of sex hormone production (38) and higher gonadotropin levels (LH 
and FSH) have been reported among permanent night workers. 
Findings from the present study suggest a direct effect of night shift work on steroid sex 
hormone production that is independent of melatonin. We have previously reported from the 
same study that exposure to permanent night shift work was associated with lower aMT6s levels 
compared to day workers (39). It has been suggested that higher levels of steroid hormones might 
be related to light-induced melatonin suppression that occurs with night working (11). Melatonin 
may modulate sex hormone production, downregulating the hypothalamus-pituitary-gonadal axis 
and possibly inhibiting aromatase, an enzyme that transforms androgens into estrogens (17, 40). 
At high levels exogenous melatonin reduces estrogen, androgen and gonadotropins, as 
demonstrated by some, but not all, clinical trials (41-45). We found no association between 
endogenous 24-h urinary levels of aMT6s and a range of steroid hormones and metabolites. 
Other studies evaluating endogenous melatonin have shown negative (46-48), null (15, 20, 21, 
49) and positive associations (12) with plasma sex hormones, therefore the interrelation between 
melatonin and sex hormone levels is not yet confirmed. 
 Another novel finding of the study is the later peak time of androgen production observed 
among night shift workers, particularly among men. Previous studies have only compared levels 
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of steroid hormones based on a single morning blood sample and therefore lacked assessment of 
steroid hormone rhythmicity and peak time of production (12, 15, 16, 20, 21, 36). Sex-hormones 
and gonadotropins show some daily variation in plasma (50-53), although steroid metabolite 
rhythms have not been well studied in urine (54). Night shift workers are exposed to irregular 
light/dark cycles but also disturbed sleep/wake patterns that disrupt the worker´s circadian timing 
organization (55). In the present study, 6-sulfatoxymelatonin acrophase, a reliable marker of 
circadian phase, was positively correlated with some of the androgens´ peak times, suggesting 
that these rhythms are partly driven by the central SCN clock. Some sex hormones such as 
testosterone can also be strongly influenced by sleep, particularly its timing and duration (56, 57). 
Controlling for self-reported sleep duration in analysis of the current data did not affect the 
results. However, since night shift work is closely linked to daytime sleep, it is possible that the 
observed effect on the peak time of androgen production is also due in part to acute sleep 
restriction. In the current study the observed differences between men and women are probably 
not due to sex, but likely are related to differences in the shift schedules that the men and women 
experienced including the intensity of the shift schedules (5 vs 3 consecutive nights), the shift 
length (10 h vs 8 h), the end time of the shift (06:00 h vs 07:00 h) and the light intensity in the 
work place, all of which would have led to different daily sleeping, eating and light exposure 
patterns. 
The extensive evaluation of hormone production in night shift workers by measuring a large 
number of metabolites together with multiple urine sample collections over a complete 24-h 
period is a strength of the current study. The use of individual cosinor analysis enabled us to 
determine the daily variation of aMT6s and sex steroid hormones, and overcome the limitation of 
comparing samples that are collected at different time-points. An earlier study (58) proposed a 
metric for night shift work based on the use of post sleep/post work ratio of urinary 6-
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hydroxymelatonin sulfate melatonin to help identify workers at increased risk for accidents or 
injuries. The use of this metric and its extension to include other hormones goes beyond the 
objectives of the current analysis. Although the timing of the urine collections across the 24-h 
period differed between individuals, being natural voids, this would not have affected the cosine-
derived parameters (mesor, acrophase). The goodness of fit of the cosine curve for melatonin was 
high, as expected for this SCN-driven endogenous rhythm. The goodness of fits for the sex 
hormones were lower indicating a less marked, though present, daily rhythm. An additional asset 
of the study is the inclusion of a sample of workers including both sexes and different 
occupational settings that facilitates extrapolation of the results to larger populations of 
permanent night shift workers. However, in subgroup analysis (by menopausal status or 
menstrual cycle phase), numbers were small and thus accuracy was reduced. Another limitation 
of this study is that the menstrual cycle phase calculation was based on the date of the last 
menstruation prior to and not following participation/urine collection and that premenopausal 
women were not able to be studied during the same menstrual cycle phase. Results, however, 
were very similar between women in the different menstrual cycle phases. All the measured 
urinary biomarkers are primary liver and kidney metabolites of the hormones, thus, the 
associations described might also reflect potential effects of night shift work on these organs and 
peripheral metabolism rather than changes solely in the organs of primary hormone synthesis 
(pineal, gonads, adrenals). Although day and night workers might differ with respect to lifestyle 
and reproductive characteristics, we carefully controlled analysis for potential confounders. 
Predictors may differ between sex hormones and metabolites, however, for simplicity we 
adjusted all sex hormone models for the same confounders although the sets of confounders for 
peak time and levels were selected separately.  
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In summary, this study shows an association between permanent night shift work and 
increased urinary levels of androgens and progestagens in both sexes, independent of melatonin 
suppression. In addition, like melatonin, peak androgen production was delayed among night 
shift workers. The higher sex hormone levels and mistimed hormone production may reflect a 
more generalized hormonal disruption that goes beyond melatonin suppression and estrogen 
increase described by the classical “melatonin hypothesis” for the link between night shift and 
hormone-dependent cancers. 
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Figure legends 
 
Figure 1 legend. Estimated geometric mean ratio (GMR) and 95% confidence intervals of 
individual 24-h mean metabolite levels (mesor) in night workers compared to day workers in men 
and premenopausal women† 
Figure 1 footnote: †Adjusted for age, body mass index (BMI), menstrual cycle phase (follicular, 
mid-cycle, luteal) 
 
Figure 2 legend. Estimated hours of difference (geometric mean difference (GMD) and 95% 
confidence interval) in individual metabolites´ peak time (acrophase) between night and day 
workers in men and premenopausal women†  
Figure 2 footnote: †Adjusted for age, body mass index (BMI), menstrual cycle phase (follicular, 
mid-cycle, luteal) and chronotype 
 
Table 1. Sociodemographic characteristics of day and night workers by sex  
Men Women 
Day (N=21) Night (N=39) Day (N=20) Night (N=33) 
N % N % N % N % 
Age (yrs) ; mean (SD) 38.4 (9.2) 39.9 (9.8) 44.9 (8.8) 49.5 (8.7) 
BMI (kg/m2) ; mean (SD) 26.0 (3.4) 26.6 (4.0) 24.4 (4.7) 24.6 (4.3) 
Highest education 
high school 18 85.7 27 82.1 6 30 11 33.3
university 3 14.3 7 17.9 14 70 22 66.7 
Working sector  
hospitals 0 0 4 10.3 19 95 32 97.0 
car factory 12 57.1 18 46.2 0 0 0 0 
train company 9 42.9 17 43.6 1 5.0 1 3.0 
Working hours/week 37.3 (1.5) 32.8 (1.2)* 37.4 (1.7) 35.2 (0.5) 
Nights worked over last 2 weeks; mean (SD) 0 6.8 (0.4)* 0 5.2 (0.3)* 
Consecutive nights worked; mean (SD) 0 2.8 (1.4)  0 2.0 (0.4) 
Total years of night work; mean (SD) 2.1 (3.0) 10.8 (8.3)* 2.2 (3.1) 15.4 (11.3)* 
Morningness-Eveningness score; mean (SD) 55.2 (6.1) 48.4 (9.1)* 50.4 (8.5) 46.7 (8.0)* 
Diurnal preference 
evening 1 4.8 8 20.5 4 20.0 8 24.2 
neither 15 71.4 27 69.2 13 65.0 22 66.7 
morning 5 23.8 4 10.3 3 15.0 3 9.1 
Current smoker 9 42.9 13 33.3 6 30.0 10 30.0 
Any alcohol use last 24 h 3 14.3 13 33.3 3 15.0 6 18.2 
Any physical activity last 24 h 8 38.1 15 38.5 10 50.0 13 39.4 
Any sleep problems 20 95.2 38 97.4 17 85.0 30 90.9 
Caffeinated drinks last 24 h; mean (SD) 2.8 (1.7) 2.6 (1.7) 2.9 (2.4) 2.3 (1.8) 
Sleep duration last 24 h; mean (SD) 5.6 (0.8) 6.4 (1.7)* 6.4 (0.9) 6.2 (1.9) 
Hours of sunlight last 24 h; mean (SD) 13.6 (0.6) 13.8 (0.9) 13.7 (1.3) 13.2 (1.3) 
Time spent outdoors  last 24 h 
1-2 hours 10 47.6 26 66.7 11 55.0 24 72.7 
≥3  hours 11 52.4 13 33.3 9 45.0 9 27.3 
Chronic health problems 5 23.8 17 43.6 6 30.0 19 57.6 
Any drug use 4 19.1 13 33.3 7 35.0 22 66.7 
Premenopausal  women 16 80.0 16 48.5 
Menstrual cycle phase† 
follicular 8 50.0 8 50.0 
mid-cycle 5 31.2 3 18.8 
luteal 3 18.8 5 31.2 
Irregular menstrual cycle  4 20.0 10 30.3 
Ever parous 16 80.0 30 90.9 
1 or 2 children 13 65.0 22 66.7 
3 or more 3 15.0 8 24.2 
Age at first full-term birth; mean (SD) 22.8 (12.6) 25.8 (9.9) 
*p for difference<0.05 for the two-sided chi-square for categorical and t test or Wilcoxon rank-sum test for 
continuous variables, †Percentages calculated among premenopausal women 
Table 2. Mean 24-h metabolite levels (mesor) in day and night workers by sex and menopausal status† 
 Men Premenopausal women Postmenopausal women 
Metabolite
†
 
 
Day workers 
(N=21) 
Night workers 
(N=39) 
Day workers 
(N=16) 
Night workers 
(N=16) 
Day workers 
(N=4) 
Night workers 
(N=17) 
 GM (GSD) GM (GSD) GM (GSD) GM (GSD) GM (GSD) GM (GSD) 
Melatonin       
6-sulfatoxymelatonin 14.0 (1.8) 10.5 (1.9) 17.9 (2.2) 10.4 (2.0)* 14.5 (2.7) 12.5 (1.7) 
Estrogens       
estradiol 1.0 (2.0) 1.1 (1.6) 3.9 (2.4) 4.2 (4.5) 1.2 (2.0) 1.2 (4.3) 
estrone 3.0 (1.6) 2.7 (1.8) 7.5 (2.0) 8.5 (3.6) 1.4 (2.0) 3.3 (2.4) 
estriol 1.6 (2.6) 2.0 (2.0) 9.1 (2.4) 11.2 (6.4) 4.2 (2.2) 4.3 (2.2) 
Total estrogens 6.1 (1.5) 6.1 (1.6) 21.3 (2.2) 26.3 (4.3) 7.3 (1.8) 9.4 (2.3) 
Progestagens       
pregnanediol 96.9 (3.3) 125.5 (2.0) 372.0 (3.0) 1094.1 (3.2)* 228.8 (1.8) 250.5 (2.5) 
pregnanetriol 334.0 (4.0) 417.5 (1.5) 581.4 (1.9) 966.5 (2.4) 378.9 (1.6) 462.3 (2.6) 
16-androstenol 486.5 (3.0) 469.3 (2.8) 276.5 (3.6) 665.7 (2.9)* 384.6 (1.5) 285.6 (3.2) 
Total progestagens 954.5 (3.4) 1 114.1 (1.7) 1 457.9 (2.1) 3 289.2 (2.2)* 1 009.5 (1.6) 1 099.9 (2.4) 
Androgens       
testosterone 13.0 (3.0) 14.5 (2.5) 4.0 (2.6) 8.0 (2.0)* 3.5 (3.5) 5.5 (2.3) 
epitestosterone 16.2 (3.9) 15.6 (2.0) 9.5 (1.8) 13.6 (2.5) 2.3 (2.5) 5.0 (1.8)* 
DHEA 16.7 (2.3) 20.2 (1.7) 25.4 (2.1) 38.7 (2.2) 23.8 (1.6) 22.0 (2.1) 
androsterone 796.4 (4.5) 1117.8 (1.5) 684.7 (1.7) 881.1 (2.1) 489.8 (1.3) 412.6 (1.9) 
etiocholanolone 795.8 (4.3) 936.1 (1.6) 1089.2 (1.6) 1195.4 (1.8) 679.8 (1.3) 764.9 (2.0) 
11β-OH-androsterone 227.1 (4.5) 307.1 (1.6) 397.7 (2.1) 555.7 (2.3) 501.6 (1.8) 556.7 (2.3) 
4-androstenedione 1.1 (1.6) 1.2 (1.6) 2.0 (2.0) 2.8 (2.1) 1.1 (2.9) 1.2 (4.3) 
6α-OH-androstenedione 0.5 (2.0) 0.6 (1.5) 1.1 (2.3) 1.8 (2.4) 0.9 (2.9) 3.3 (2.4) 
3α,5α-androstanediol 29.5 (3.7) 39.7 (1.6) 21.3 (1.9) 36.2 (2.2)* 23.6 (1.6) 4.3 (2.2) 
3α,5β-androstanediol 52.0 (4.0) 60.1 (2.2) 35.7 (2.9) 62.2 (3.3) 50.6 (3.3) 250.5 (2.5) 
Total androgens 2070.6 (3.8) 2613.3 (1.4) 2498.7 (1.4) 3082.1 (1.8) 1870.8 (1.3) 1 989.9 (1.9) 
GM: geometric mean; GSD: geometric standard deviation; DHEA: dehydroepiandrosterone, †Levels of metabolites are expressed in ng/mg creatinine/hour  
*p for difference<0.05 for two-sided t test using the log-transformed variable 
Table 3. Estimated geometric mean ratio (GMR) and 95% confidence interval (CI) of 24-h mean metabolite 
levels (mesor) in night workers compared to day workers in the full study population (N=113). 
 
Mean levels (mesor) 
Metabolite 
 GMR (95% CI)
† GMR (95% CI)††      GMR (95% CI)
†† † 
(+aMT6s levels) 
Melatonin    
6-sulfatoxymelatonin 0.72 (0.55, 0.93) 0.67 (0.51, 0.89) - 
Estrogens    
estradiol 1.08 (0.74, 1.57) 1.20 (0.83, 1.74) 1.36 (0.93, 1.99) 
estrone 1.09 (0.81, 1.47) 1.17 (0.86, 1.59) 1.28 (0.94, 1.75) 
estriol 1.11 (0.76, 1.63) 1.05 (0.68, 1.62) 1.19 (0.76, 1.85) 
Total estrogens 1.08 (0.80, 1.46) 1.19 (0.86, 1.64) 1.21 (0.87, 1.67) 
Progestagens    
pregnanediol 1.61 (1.11, 2.34) 1.74 (1.15, 2.64) 1.88 (1.22, 2.89) 
pregnanetriol 1.40 (1.00, 1.96) 1.46 (1.06, 2.01) 1.55 (1.11, 2.17) 
16-androstenol 1.28 (0.83, 1.98) 1.32 (0.84, 2.08) 1.41 (0.88, 2.27) 
Total progestagens 1.44 (1.05, 1.97) 1.65 (1.17, 2.32) 1.67 (1.18, 2.35) 
Androgens    
testosterone 1.42 (0.98, 2.06) 1.43 (0.95, 2.14) 1.57 (1.03, 2.38) 
epitestosterone 1.20 (0.85, 1.71) 1.16 (0.80, 1.69) 1.27 (0.86, 1.88) 
DHEA 1.31 (1.01, 1.72) 1.38 (1.05, 1.82) 1.44 (1.08, 1.92) 
androsterone 1.31 (0.95, 1.82) 1.40 (0.97, 2.02) 1.52 (1.04, 2.22) 
etiocholanolone 1.15 (0.84, 1.58) 1.23 (0.86, 1.76) 1.37 (0.94, 1.98) 
11β-OH-androsterone 1.33 (0.93, 1.90) 1.42 (0.99, 2.04) 1.54 (1.06, 2.25) 
4-androstenedione 1.29 (0.99, 1.69) 1.36 (1.05, 1.78) 1.43 (1.08, 1.89) 
6α-OH-androstenedione 1.40 (1.04, 1.89) 1.41 (1.09, 1.84) 1.48 (1.13, 1.95) 
3α,5α-androstanediol 1.41 (1.03, 1.94) 1.38 (0.99, 1.91) 1.47 (1.05, 2.07) 
3α,5β-androstanediol 1.27 (0.80, 2.00) 1.32 (0.87, 2.02) 1.49 (0.96, 2.30) 
Total androgens 1.24 (0.93, 1.65) 1.44 (1.03, 2.00) 1.45 (1.04, 2.02) 
DHEA: dehydroepiandrosterone 
†Adjusted for age, sex, body mass index (BMI), menopausal status (premenopausal, postmenopausal), menstrual cycle phase 
(follicular, mid-cycle, luteal) 
††Additionally adjusted for education (primary school, high school, university), smoking status (smoker, former, never), 
physical activity last 24-h (No, ≤14 METS-hours, >14 METS-hours), alcohol consumption last 24-h (yes/no), number of 
caffeine beverages last 24-h, sleep duration last 24-h diurnal preference (M-E score), parity (nulliparous, 1-2, 3 or more 
children) and age at first full-term birth, chronic symptoms (yes/no), drug use (yes, no) and hours of sunlight last 24-h.   
†††Additionally adjusted for aMT6s level 
 
 
Table 4. Peak time (acrophase) of metabolite production (geometric mean (GM) and 95% confidence interval (CI) in day and night workers and estimated 
hours of difference in metabolites´ peak time (geometric mean difference (GMD) and 95% CI) between night and day workers. 
Peak time (acrophase)† 
GMD (95% CI)†† GMD (95% CI)
††† 
(+aMT6s peak time)Metabolite  
Day workers (N=41) 
GM (95% CI) 
Night workers (N=72) 
GM (95% CI) 
Melatonin    
6-sulfatoxymelatonin 05:36 (05:06, 06:12) 08:42 (07:48, 09:42) 2.9 (1.5, 4.3) - 
Estrogens    
estradiol 09:14 (07:05, 12:03) 08:39 (06:53, 10:52) -0.6 (-4.1, 2.9) -0.6 (-4.5, 3.3) 
estrone 08:28 (06:43, 10:38) 09:10 (07:30, 11:11) 0.1 (-2.9, 3.2) -0.8 (-4.0, 2.5) 
estriol 06:12 (04:15, 09:02) 08:58 (07:38, 10:34)* 2.2 (-0.9, 5.2) 1.7 (-1.6, 5.0) 
Progestagens    
pregnanediol 08:46 (06:49, 11:16) 09:20 (07:37, 11:25) -0.3 (-3.6, 3.0) -1.1 (-4.7, 2.5) 
pregnanetriol 10:01 (07:55, 12:40) 10:35 (08:36, 13:02) 0.4 (-3.4, 4.1) 0.2 (-3.9, 4.3) 
16-androstenol 12:20 (10:08, 15:03) 12:18 (10:40, 14:11) -1.0 (-4.4, 2.3) -1.5 (-5.2, 2.1) 
Androgens    
testosterone 08:35 (06:52, 10:46) 12:14 (10:06, 14:48)* 3.2 (-0.6, 6.9) 1.3 (-2.6, 5.2) 
epitestosterone 09:11 (08:03, 10:28) 13:35 (11:26, 16:07)* 5.8 (2.5, 9.2) 4.6 (1.1, 8.2) 
DHEA 10:24 (08:03, 10:28) 13:43 (12:18, 15:17)* 3.4 (0.6, 6.2) 2.8 (-0.3, 5.8) 
androsterone 11:33 (09:54, 13:29) 13:04 (11:34, 14:47) 0.7 (-2.0, 3.5) 0.7 (-2.3, 3.7) 
etiocholanolone 09:46 (07:56, 11:59) 12:40 (11:20, 14:09)* 2.8 (0.1, 5.6) 2.2 (-0.8, 5.3) 
11β-OH-androsterone 11:59 (10:27, 13:44) 12:38 (11:08, 14:22) 0.3 (-2.4, 3.0) 0.0 (-2.9, 2.9) 
4-androstenedione 08:28 (06:25, 11:11) 10:55 (08:52, 13:26) 2.8 (-1.2, 6.8) 2.5 (-1.9, 6.8) 
6α-OH-androstenedione 11:37 (10:20, 13:03) 12:52 (11:10, 14:52) 3.1 (0.1, 6.0) 2.8 (-0.4, 6.0) 
3α,5α-androstanediol 08:37 (06:31, 11:23) 11:28 (09:15, 14:13) 2.3 (-1.7, 6.3) 2.0 (-2.4, 6.3) 
3α,5β-androstanediol 08:40 (06:50, 10:58) 11:13 (09:33, 13:12) 3.1 (-0.1, 6.3) 2.2 (-1.3, 5.6) 
DHEA: dehydroepiandrosterone 
†Peak time is expressed in local time;  
††Adjusted for age, diurnal preference (M-E score), education (primary school, high school, university), sex, menopausal status (premenopausal, postmenopausal), parity 
(nulliparous, 1-2, 3 or more children), age at first full-term birth, body mass index (BMI), physical activity last 24-h (No, ≤14 METS-hours, >14 METS-hours), number 
of caffeinated beverages last 24-h, sleep duration last 24-h, sleep problems (yes/no), chronic symptoms (yes/no), drug use (yes, no) and hours of sunlight last 24 h;  
†††Additionally adjusted for aMT6s peak time;   
*p for difference<0.05 for two-sided t test using log-transformed variable 


